IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple… EP News Bureau Jun 4, 2025 TRIgnite-1 study shows 79 per cent response rate and no dose-limiting toxicities in early-stage trial of BCMA × CD38 × CD3…
Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT… EP News Bureau Dec 10, 2024 ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)
